查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1937923

全球連續性腎臟替代療法（CRRT）市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Continuous Renal Replacement Therapy Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 172 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計連續性腎臟替代療法 (CRRT) 市場規模將從 2025 年的 23.4 億美元成長到 2034 年的 47 億美元，2026 年至 2034 年的複合年成長率為 8.07%。

隨著急性腎損傷（AKI）和慢性腎臟病（CKD）在全球範圍內的發病率持續上升，連續性腎臟替代療法（CRRT）市場預計將迎來顯著成長。 CRRT是治療方法嚴重腎功能障礙患者的關鍵手段，它提供持續且溫和的透析，以維持體液和電解質平衡。糖尿病和高血壓等腎臟疾病的主要危險因素，其發病率的不斷上升正在推動對CRRT解決方案的需求。此外，人口老化以及需要腎臟支持的嚴重病患數量的增加，也進一步加速了市場擴張。

技術創新在塑造CRRT市場未來中發揮關鍵作用。透析設備的創新，包括改進的過濾技術和人性化的介面，正在提高CRRT治療的效率和效果。此外，遠距監測和遠端醫療解決方案的整合使醫療服務提供者能夠更有效地管理CRRT治療，從而確保改善患者的治療效果。隨著製造商持續加大研發投入，預計CRRT市場將在包括醫院和門診診所在內的各種醫療機構中得到更廣泛的應用。

此外，CRRT市場也受到以病人為中心的照護和個人化醫療日益重視的影響。隨著醫療服務提供者尋求根據患者的個人需求量身定做治療方案，對能夠提供可自訂設置和治療通訊協定的CRRT系統的需求日益成長。這一趨勢正在推動能夠適應患者特定需求的先進CRRT解決方案的開發，從而改善整體治療效果。隨著市場的不斷發展，技術、個人化和病人參與的整合將是成功的關鍵。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 繪製滲透率和成長前景圖
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制
    • 市場機遇
    • 市場問題
  • 波特五力分析
  • PESTLE分析

第4章 全球連續性腎臟替代療法（CRRT）市場依模式分類

  • 市場分析、洞察與預測
  • 慢速連續超過濾（SCUF）
  • 連續性靜脈-靜脈血液濾過（CVVHF）
  • 連續性靜脈-靜脈血液透析（CVVHD）
  • 連續性靜脈-靜脈血液透析濾過（CVVHDF）

5. 全球連續性腎臟替代療法 (CRRT) 產品市場

  • 市場分析、洞察與預測
  • 透析和置換液
  • 一次性產品
  • 系統

6. 全球連續性腎臟替代療法 (CRRT) 市場

  • 市場分析、洞察與預測
  • 腎
  • 非腎臟
  • 組合

7. 全球連續性腎臟替代療法 (CRRT) 市場（按最終用戶分類）

  • 市場分析、洞察與預測
  • 醫院
  • 診所
  • 其他

8. 全球連續性腎臟替代療法 (CRRT) 市場（按地區分類）

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商格局（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Fresenius Medical Care AG & Co. KGaA
    • Baxter International Inc
    • B. Braun Melsungen AG
    • Nipro Corporation
    • Asahi Kasei Corporation
    • Medtronic
    • DaVita Inc
    • NxStage MedicalInc
    • Toray Medical Company Limited
    • Astellas Pharma Inc
    • CytoSorbents Corp
    • Infomed SA
    • Medica SPA
    • Medical Components Inc
    • Medites Pharma Spol. SRO
簡介目錄
Product Code: VMR11218337

The Continuous Renal Replacement Therapy Market size is expected to reach USD 4.70 Billion in 2034 from USD 2.34 Billion (2025) growing at a CAGR of 8.07% during 2026-2034.

The Continuous Renal Replacement Therapy (CRRT) Market is poised for significant growth as the prevalence of acute kidney injury (AKI) and chronic kidney disease (CKD) continues to rise globally. CRRT is a vital treatment modality for patients with severe renal impairment, providing continuous and gentle dialysis to maintain fluid and electrolyte balance. The increasing incidence of conditions such as diabetes and hypertension, which are major risk factors for kidney disease, is driving demand for CRRT solutions. Additionally, the growing aging population and the rising number of critically ill patients requiring renal support are further propelling market expansion.

Technological advancements are playing a crucial role in shaping the future of the CRRT market. Innovations in dialysis machines, including improved filtration technologies and user-friendly interfaces, are enhancing the efficiency and effectiveness of CRRT treatments. Furthermore, the integration of remote monitoring and telehealth solutions is enabling healthcare providers to manage CRRT therapies more effectively, ensuring better patient outcomes. As manufacturers continue to invest in research and development, the CRRT market is likely to see increased adoption across various healthcare settings, including hospitals and outpatient clinics.

Moreover, the growing emphasis on patient-centered care and personalized medicine is influencing the CRRT market. As healthcare providers seek to tailor treatments to individual patient needs, there is a rising demand for CRRT systems that offer customizable settings and treatment protocols. This trend is driving the development of advanced CRRT solutions that can adapt to the specific requirements of patients, improving overall treatment efficacy. As the market continues to evolve, the integration of technology, personalization, and patient engagement will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Mode

  • Slow Continuous Ultrafiltration (SCUF)
  • Continuous Venovenous Hemofiltration (CVVHF)
  • Continuous Venovenous Haemodialysis (CVVHD)
  • Continuous Venovenous Hemodiafiltration (CVVHDF)

By Product

  • Dialysates And Replacement Fluids
  • Disposables
  • Systems

By Therapy

  • Renal
  • Non-renal
  • Combination

By End User

  • Hospitals
  • Clinics
  • Others

COMPANIES PROFILED

  • Fresenius Medical Care AG Co KGaA, Baxter International Inc, B Braun Melsungen AG, Nipro Corporation, Asahi Kasei Corporation, Medtronic, DaVita Inc, NxStage Medical, Inc, Toray Medical Company Limited, Astellas Pharma Inc, CytoSorbents Corp, Infomed SA, Medica SPA, Medical Components Inc, Medites Pharma spol sro

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: BY MODE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Mode
  • 4.2. Slow Continuous Ultrafiltration (SCUF) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Continuous Venovenous Hemofiltration (CVVHF) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Continuous Venovenous Haemodialysis (CVVHD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Continuous Venovenous Hemodiafiltration (CVVHDF) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Product
  • 5.2. Dialysates And Replacement Fluids Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Disposables Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Systems Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: BY THERAPY 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Therapy
  • 6.2. Renal Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Non-renal Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Combination Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: BY END USER 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End User
  • 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: BY REGION 2022-2034(USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Mode
    • 8.2.2 By Product
    • 8.2.3 By Therapy
    • 8.2.4 By End User
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Mode
    • 8.3.2 By Product
    • 8.3.3 By Therapy
    • 8.3.4 By End User
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Mode
    • 8.4.2 By Product
    • 8.4.3 By Therapy
    • 8.4.4 By End User
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Mode
    • 8.5.2 By Product
    • 8.5.3 By Therapy
    • 8.5.4 By End User
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Mode
    • 8.6.2 By Product
    • 8.6.3 By Therapy
    • 8.6.4 By End User
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Fresenius Medical Care AG & Co. KGaA
    • 10.2.2 Baxter International Inc
    • 10.2.3 B. Braun Melsungen AG
    • 10.2.4 Nipro Corporation
    • 10.2.5 Asahi Kasei Corporation
    • 10.2.6 Medtronic
    • 10.2.7 DaVita Inc
    • 10.2.8 NxStage MedicalInc
    • 10.2.9 Toray Medical Company Limited
    • 10.2.10 Astellas Pharma Inc
    • 10.2.11 CytoSorbents Corp
    • 10.2.12 Infomed SA
    • 10.2.13 Medica SPA
    • 10.2.14 Medical Components Inc
    • 10.2.15 Medites Pharma Spol. S.R.O